Modus Therapeutics Holding AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was SEK 2.91 million compared to SEK 4.44 million a year ago. Basic loss per share from continuing operations was SEK 0.18 compared to SEK 0.3 a year ago.
For the nine months, net loss was SEK 8.96 million compared to SEK 8.4 million a year ago. Basic loss per share from continuing operations was SEK 0.56 compared to SEK 0.76 a year ago.